ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
HC1108_COVID_Manuscript_Original.pdf (892.68 kB)
0/0

A Promising Strategy Against SARS-CoV-2 Infected Patients: Antisense Therapy

preprint
submitted on 12.09.2020 and posted on 14.09.2020 by Hasan Cubuk

As of July 25-2020, 643,412 people in more than 215 countries have been victims of the new type of coronavirus, SARS-CoV-2. Thereby, there is a huge effort to develop a strategy to treat, and or prevent people from SARS-CoV-2 infection. Those efforts could be mainly categorized as drug repurposing, anti-SARS-CoV-2 antibodies from people who recovered, and vaccines. However, there is currently no specific treatment available against SARS-CoV-2 infected patients. That`s why many new approaches and ideas are still studied every day for the treatment of SARS-CoV-2 infected patients. Antisense therapy is one of these promising approaches to target SARS-CoV-2 genomic RNA specifically and inhibit its activity upon incorrect viral RNA processing. In this study, antisense oligonucleotide (ASO) candidates targeting SARS-CoV-2 genomic RNA were designed. High-scored ASOs with a high potential to inhibit SARS-CoV-2 replication and transcription by inducing cleavage of the viral genomic were determined among ASO candidates. For the future, those promising ASOs can be synthesized followed by required modifications and test on SARS-CoV-2 infected Vero cells to screen their efficacy for the treatment of SARS-CoV-2 infected patients.


Funding

Not funded.

History

Email Address of Submitting Author

hasan.cubk@hotmail.com

Institution

Istanbul AREL University

Country

Turkey

ORCID For Submitting Author

0000-0001-6203-4132

Declaration of Conflict of Interest

No conflict of interest

Version Notes

This is a revised version.

Exports